Heartflow Inc

HTFL

Market cap $2.02B

MOUNTAIN VIEW, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley Technology, Media & Telecom Conference. The presentation will take place in San Francisco, CA, on Tuesday, March 3, 2026, at 10:45 a.m. PT / 1:45 p.m. ET.

2025 US IPOs emerged out of a tumultuous April with strong price momentum going into the summer. US IPOs under $100 million in proceeds continued to perform poorly in 2025 after also struggling in 2024, with the less than $50 million issues declining 18.4% this year compared to a 17.1% decline last year. The strong performance of US technology IPOs during the first half of 2025 set the stage nicely for more issuers to go public during the second half of the year.

MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026.

We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.

HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans.

MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.

Jeffrey Lightcap, a member of the Board of Directors of HeartFlow (HTFL 2.00%), acquired 40,000 common shares in an open-market transaction valued at $1,053,680 on Dec. 16, 2025; see SEC Form 4 filing.

The specialized healthcare diagnostics company earned two endorsements from heart health organizations. These concerned HeartFlow's plaque detection product.

Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment